Your browser doesn't support javascript.
loading
Natural ingredients from Chinese materia medica for pulmonary hypertension.
Zhang, Jia-Rui; Ouyang, Xuan; Hou, Chi; Yang, Qi-Feng; Wu, Yingjun; Lu, Wen-Ju; Liu, Chun-Li; Yang, Kai; Zhong, Nan-Shan; Wang, Jian; Chen, Yu-Qin.
Afiliação
  • Zhang JR; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Ouyang X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Hou C; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Yang QF; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Wu Y; The Second Affiliated Hospital of Guangzhou medical university, 250 Changgangdong Rd, Guangzhou 51026, China.
  • Lu WJ; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Liu CL; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Yang K; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Zhong NS; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Wang J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
  • Chen YQ; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital
Chin J Nat Med ; 19(11): 801-814, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34844719
ABSTRACT
Pulmonary hypertension (PH) is a severe pathophysiological condition characterized by pulmonary artery remodeling and continuous increases in pulmonary artery pressure, which may eventually develop to right heart failure and death. Although newly discovered and incredible treatment strategies in recent years have improved the prognosis of PH, limited types of effective and economical drugs for PH still makes it as a life-threatening disease. Some drugs from Chinese materia medica (CMM) have been traditionally applied in the treatment of lung diseases. Accumulating evidence suggests active pharmaceutical ingredients (APIs) derived from those medicines brings promising future for the prevention and treatment of PH. In this review, we summarized the pharmacological effects of APIs derived from CMM which are potent in treating PH, so as to provide new thoughts for initial drug discovery and identification of potential therapeutic strategies in alternative medicine for PH.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Materia Medica / Hipertensão Pulmonar Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Chin J Nat Med Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Materia Medica / Hipertensão Pulmonar Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Chin J Nat Med Ano de publicação: 2021 Tipo de documento: Article